NASD · Healthcare · Biotechnology · USA
Exelixis Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Exelixis is an oncology company with four marketed pharmaceutical products. Cabozantinib, marketed as CABOMETYX and COMETRIQ, treats renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and neuroendocrine tumors. The company also markets COTELLIC for melanoma through Genentech and MINNEBRO for hypertension in Japan through Daiichi Sankyo.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Exelixis Inc stock.
Undervalued: intrinsic value $79.57 per share, market price $62.68, margin of safety 21.2% (as of 2026-10-19).
Discounting its cash flows at 8.1% (average of 3 methods) values the shares at $79.57; the price of $62.68 is 21% below that value, and 79% of that value comes from beyond year five.
Leak Score: 100/100 on 11 of 12 signals (Major Leak).
17 more funds hold it; the full list is part of the paid plan.
14 more in this industry show a wider margin of safety.
EXEL is undervalued (as of the 2026-10-19 close). Discounting its cash flows at 8.1% (average of 3 methods) values the shares at $79.57; the price of $62.68 is 21% below that value, and 79% of that value comes from beyond year five.
$79.57 per share (as of the 2026-10-19 close), against a market price of $62.68. That is a margin of safety of 21.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
100 out of 100, which we rate "Major Leak", on 11 of 12 value investing signals.